{"id":"pq-0-75","safety":{"commonSideEffects":[{"rate":null,"effect":"Hemolysis in G6PD-deficient patients"},{"rate":null,"effect":"Abdominal discomfort"},{"rate":null,"effect":"Methemoglobinemia"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL439259","moleculeType":"Small molecule","molecularWeight":"341.80"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PQ (primaquine at 0.75 mg/kg dose) eliminates dormant liver forms (hypnozoites) of P. vivax and P. ovale malaria parasites, preventing relapse infections. It works by generating reactive oxygen species within infected hepatocytes, thereby achieving radical cure of these relapsing malaria species. The 0.75 dose represents a lower-dose regimen studied for improved tolerability.","oneSentence":"PQ is a primaquine analog that acts as an 8-aminoquinoline antimalarial targeting the hypnozoite stage of Plasmodium parasites in the liver.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:29:45.861Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Radical cure of Plasmodium vivax malaria (hypnozoite elimination)"},{"name":"Radical cure of Plasmodium ovale malaria (hypnozoite elimination)"},{"name":"Prevention of malaria relapse in endemic regions"}]},"trialDetails":[{"nctId":"NCT06068530","phase":"PHASE4","title":"Mass Vaccine and Drug Administration, Bangladesh","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-02-15","conditions":"Plasmodium Falciparum Malaria","enrollment":10000},{"nctId":"NCT01838902","phase":"PHASE3","title":"Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2013-08","conditions":"Malaria","enrollment":467},{"nctId":"NCT02535767","phase":"PHASE1, PHASE2","title":"Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2015-08","conditions":"Malaria","enrollment":28},{"nctId":"NCT01389557","phase":"PHASE4","title":"Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2011-02","conditions":"Malaria","enrollment":77},{"nctId":"NCT01392014","phase":"PHASE4","title":"Dihydroartemisinin-piperaquine and Primaquine for Uncomplicated Plasmodium Falciparum Cases","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2008-12","conditions":"Malaria","enrollment":374}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":77,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Primaquine"],"phase":"phase_3","status":"active","brandName":"PQ (0.75)","genericName":"PQ (0.75)","companyName":"London School of Hygiene and Tropical Medicine","companyId":"london-school-of-hygiene-and-tropical-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PQ is a primaquine analog that acts as an 8-aminoquinoline antimalarial targeting the hypnozoite stage of Plasmodium parasites in the liver. Used for Radical cure of Plasmodium vivax malaria (hypnozoite elimination), Radical cure of Plasmodium ovale malaria (hypnozoite elimination), Prevention of malaria relapse in endemic regions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}